About Us

Who we are

Black Swan Analysis, founded in 2007, is a unique analysis practice that provides robust valuations and commercialisation plans to optimise products in the healthcare industry. We know what it takes to succeed in this industry -we've seen what works and what doesn't and we are committed to bringing insight and high quality solutions to our clients. In doing so, we help them meet the many challenges of today's complex healthcare marketplace.

The Black Swan Analysis team has extensive experience in the Nuclear Medicine field with the development and successful commercialisation of F18 radio-labelled PET products. They have launched products across the EU market and are very familiar with the challenges and constraints of F18 production, product labelling & supply chain constraints.